Results 31 to 40 of about 45,299 (154)

Drug-disease networks and drug repurposing. [PDF]

PLoS Comput Biol
Abstract Repurposing existing drugs to treat new diseases is a cost-effective alternative to de novo drug development, but there are millions of potential drug-disease combinations to be considered with only a small fraction being viable.
Polanco A, Newman MEJ.
europepmc   +4 more sources

Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors

Pharmacology Research & Perspectives
Cancer medicines often have narrow therapeutic windows; toxicity can be severe and sometimes fatal, but inadequate dose intensity reduces efficacy and survival.
Jennifer H. Martin, Peter Galettis, Alex Flynn, Jennifer Schneider   +3 more
doaj   +1 more source

A novel drug repurposing approach for non-small cell lung cancer using deep learning.

PLoS ONE, 2020
Drug repurposing is an attractive and pragmatic way offering reduced risks and development time in the complicated process of drug discovery. In the past, drug repurposing has been largely accidental and serendipitous. The most successful examples so far
Bingrui Li, Chan Dai, Lijun Wang, Hailong Deng, Yingying Li, Zheng Guan, Haihong Ni   +6 more
doaj   +1 more source

Old Drugs, New Indications (Review)

Разработка и регистрация лекарственных средств, 2023
Introduction. The drug can be used in the treatment of one disease and for the prevention and treatment of another pathological process. This is possible due to the repurposing of medicines.
I. I. Miroshnichenko, E. A. Valdman, I. I. Kuz'min   +2 more
doaj   +1 more source

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

Health Informatics Journal, 2020
Due to the huge costs associated with new drug discovery and development, drug repurposing has become an important complement to the traditional de novo approach.
Yongjun Zhu, Chao Che, Bo Jin, Ningrui Zhang, Chang Su, Fei Wang   +5 more
doaj   +1 more source

A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases

Life, 2021
The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks.
Md. Mohaiminul Islam, Yang Wang, Pingzhao Hu   +2 more
doaj   +1 more source

DeCoST: A New Approach in Drug Repurposing From Control System Theory

Frontiers in Pharmacology, 2018
In this paper, we propose DeCoST (Drug Repurposing from Control System Theory) framework to apply control system paradigm for drug repurposing purpose.
Thanh M. Nguyen, Syed A. Muhammad, Sara Ibrahim, Lin Ma, Jinlei Guo, Baogang Bai, Bixin Zeng   +6 more
doaj   +1 more source

Computational drug repurposing based on electronic health records: a scoping review

npj Digital Medicine, 2022
Computational drug repurposing methods adapt Artificial intelligence (AI) algorithms for the discovery of new applications of approved or investigational drugs.
Nansu Zong, Andrew Wen, Sungrim Moon, Sunyang Fu, Liwei Wang, Yiqing Zhao, Yue Yu, Ming Huang, Yanshan Wang, Gang Zheng, Michelle M. Mielke, James R. Cerhan, Hongfang Liu   +12 more
doaj   +1 more source

A novel approach for drug discovery-drug repurposing

National Journal of Physiology, Pharmacy and Pharmacology, 2022
Drug repurposing refers to finding a new indication for a pre-existing drug. It is a novel way of drug discovery that greatly reduces the time and money spent in the drug discovery process.
Muthu Meera, Sindhu Sekar, Rajkishore Mahatao   +2 more
doaj   +1 more source

Repurposing of approved cardiovascular drugs [PDF]

Journal of Translational Medicine, 2016
Research and development of new drugs requires both long time and high costs, whereas safety and tolerability profiles make the success rate of approval very low. Drug repurposing, applying known drugs and compounds to new indications, has been noted recently as a cost-effective and time-unconsuming way in developing new drugs, because they have ...
Junichi Ishida, Masaaki Konishi, Nicole Ebner, Jochen Springer   +3 more
openaire   +3 more sources